Sun Sep 15 12:45:00 UTC 2024: ## Genmab’s Rina-S Shows Promising Results in Ovarian Cancer Treatment

**Copenhagen, Denmark, September 15, 2024** – Genmab A/S (Nasdaq: GMAB) announced today that new data from a Phase 1/2 study of rinatabart sesutecan (Rina-S) demonstrated a confirmed objective response rate (ORR) of 50.0% in ovarian cancer patients treated with the investigational drug. These results were presented at the European Society of Medical Oncology Congress 2024 (ESMO) in Barcelona, Spain.

Rina-S is an antibody-drug conjugate (ADC) that targets folate receptor-alpha (FRα) and is currently in Phase 2 development for the treatment of ovarian cancer and other FRα-expressing solid tumors. The study involved 42 previously treated patients with advanced ovarian cancer who were randomized to receive either Rina-S 100 mg/m2 or 120 mg/m2 every three weeks.

The results showed a significantly higher ORR in patients receiving Rina-S 120 mg/m2 compared to those receiving 100 mg/m2 (50.0% vs 18.2%). Importantly, these responses were observed regardless of FRα expression levels. The data also showed a high disease control rate (DCR) of 86.4% and 88.9% in the 120 mg/m2 and 100 mg/m2 groups, respectively.

“These encouraging Phase 1/2 data demonstrate the potential for Rina-S to become a new treatment option for patients with advanced ovarian cancer,” said Dr. Elizabeth Lee, a medical oncologist at Dana-Farber Cancer Institute. “We are eager to see further data from the tumor-specific dose expansion cohorts.”

Genmab has selected Rina-S 120 mg/m2 for further evaluation in a Phase 3 trial for patients with advanced ovarian cancer, which is expected to begin in 2024.

“We are encouraged by these data and believe that Rina-S has the potential to demonstrate anti-tumor activity beyond first-generation FRα-based therapies,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genmab. “Genmab is committed to evaluating the full potential of Rina-S in patients with ovarian, endometrial and other solid tumor cancers.”

Common side effects of Rina-S treatment included anemia, neutropenia, nausea, and fatigue. Dose reductions and treatment discontinuations were infrequent.

**About Ovarian Cancer**

Ovarian cancer is a major global health issue, with over 320,000 new cases diagnosed annually worldwide. It is often diagnosed at an advanced stage due to its subtle and non-specific symptoms. Platinum-based chemotherapy has been the standard treatment for ovarian cancer, but many patients experience recurrence after initial treatment.

**About Rina-S**

Rina-S is a clinical-stage, FRα-targeted, Topo1 ADC. Genmab intends to broaden the development plans for Rina-S within ovarian cancer and other FRα-expressing solid tumors. In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing platinum-resistant ovarian cancer.

This news release is based on information provided by Genmab A/S. For more information, please visit Genmab.com.

Read More